On January 30, 2026, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an extension of the indication for AKEEGA® (niraparib and abiraterone acetate dual action tablet). The recommendation covers use in combination with prednisone or prednisolone and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) who harbor germline or somatic BRCA1/2 mutations. This marks the first potential approval of a targeted PARP inhibitor–based regimen earlier in the metastatic disease pathway for this high-risk population.

The positive CHMP opinion is based on data from the international, randomized, double-blind AMPLITUDE study (n=696) comparing niraparib/abiraterone acetate plus prednisone and ADT versus placebo plus abiraterone acetate and ADT in patients with homologous recombination repair (HRR) gene alterations. In the BRCA1/2-mutated subgroup (n=191), the niraparib combination reduced the risk of radiographic progression or death by 48% versus control (hazard ratio 0.52; 95% confidence interval 0.37–0.72; p<0.0001), with median radiographic progression-free survival not yet reached versus 26 months for placebo. Time to symptomatic progression improved by 56% (HR 0.44; 95% CI 0.29–0.68; p=0.0001), and an early overall survival trend showed a 25% risk reduction (HR 0.75; 95% CI 0.51–1.11; p=0.15) in favor of the experimental arm.

Safety data from AMPLITUDE indicate that the niraparib/abiraterone acetate combination has a tolerability profile consistent with prior studies in metastatic castration-resistant disease. The most frequent Grade 3/4 adverse events were anemia and hypertension. Despite these events, discontinuations due to adverse events remained low, and most toxicities were manageable through dose modifications and supportive measures. These findings reinforce the feasibility of integrating the dual action tablet into clinical practice for mHSPC patients with BRCA mutations.

Pending final approval by the European Medicines Agency, AKEEGA® could establish a new standard of care for approximately one in four mHSPC patients with HRR alterations, a subgroup associated with faster progression and shorter survival. The global Phase 3 trial spanned 32 countries, underscoring Johnson & Johnson’s commitment to expanding its oncology portfolio. Investors should monitor the EMA’s final decision, expected in the second half of 2026, as well as ongoing overall survival data maturation, which could drive label extensions and incremental revenue in the high-growth prostate cancer segment.